46 results about "Endothelial Growth Factor Receptor" patented technology

The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity.

The invention belongs to the technical field of genetic engineering antibodies and particularly relates to a whole human source single chain antibody which is designed and expressed by genetic engineering and has specific affinity towards human vascular endothelial growth factor receptor 2 (VEGFR-2). The invention also provides a nucleotide sequence of heavy chain variable region and light chain variable region immunoglobulin molecules, a nucleotide sequence which comprises the heavy chain variable region and light chain variable region immunoglobulin molecules, an amino acid sequence which comprises variable heavy chain and variable light chain immunoglobulin molecules, and a sequence which corresponds to CDR1, CDR2 and CDR3 of a complementary determining region. The invention also provides a method for generating and expressing the anti-VEGFR-2 single chain antibody, by cycling operations of gathering-elution-gathering, an antibody which has specific affinity towards the human vascular endothelial growth factor is screened, and then the single chain antibody is obtained through a prokaryotic cell secretion and expression system and an affinity purification system. The antibody can be coupled with a detectable substance and therapeutic agent.

The related chalketoxime shown as the formula (1) is prepared by heating and reflux reacting the 2', 4'-dihydroxy -6'-methoxyl-3', 5'-dimethylchalcone and hydroxylamine hydrochloride in pyridine, which has well solvability, fit to direct inject for drug, restrains obviously all of the activity of blood vessel endothelium growth factor receptor, HER2 receptor and Tyr kinase as PDGFR receptor, the external growth of cells for breast cancer and liver cancer, and the phosphorylation of KDR in ECV304 cell, HER2 in MDA-MB-453 cell and PDGFR receptor in C6 cell, and benefit to treat tumor.

The invention belongs to the technical field of gene engineering antibodies, and in particular relates to a preparation method and an application of a bispecific diabody of an anti-tumor epidermal growth factor receptor (EGFR) and an anti-tumor vascular endothelial growth factor (VEGFR/KDR). The bispecific diabody formed by cross-linking and expressing heavy/light chain variable areas of an anti-EGFR high-affinity single-chain antibody E10 and an anti-KDR single-chain antibody AK404 by using genetic engineering technology can simultaneously act on EGFR with high expression on the surfaces of tumor cells and KDR with high expression on the surfaces of tumor angiogenesis vascular endothelial cells, and can achieve the purposes of simultaneously inhibiting or killing tumor cells or inhibiting or damaging tumor angiogenesis.

The invention relates to indolone compounds shown as a general formula (a) or derivatives thereof and applications thereof. According to the invention, indolone compounds are substituted with deuterium to obtain deuterium-enriched indolone compounds; the indolone compounds can simultaneously act on the following three key receptor families involved in angiogenesis process: vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), so as to inhibit angiogenesis and achieve the effect of treating cancers. The deuterated indolone compounds or the derivatives thereof have the advantage of high efficiency when used asdrugs. The general formula (a) is as shown in the specification.

The invention brings forward a human vascular endothelial growth factor specifically-binding antibody or its antigen-binding fragment and an application thereof. The antibody or its antigen-binding fragment comprises a heavy-chain variable region having at least one of the following amino acid sequences: (1) an amino acid sequence as shown in SEQ ID NO:1; (2) an amino acid sequence as shown in SEQ ID NO:2; (3) an amino acid sequence as shown in SEQ ID NO:3; and (4) an amino acid sequence having more than one conserved amino acid mutations in comparison with the amino acid sequences in (1)-(3). According to the antibody or its antigen-binding fragment of the embodiment, human vascular endothelial growth factor can be specifically recognized, and binding of human vascular endothelial growth factor to its receptor can be effectively blocked so as to further block correlated signal pathways of the human vascular endothelial growth factor receptor such as VEGFR1 or 2. Thus, growth of cancer can be effectively inhibited.

The invention discloses a recombined vessel endothelium growth factor receptor, encoding genes thereof and application. The provided recombined blood vessel endothelium growth factor receptor is a fusion protein, and a structural domain 1-3 and an Fc section of a human IgG1 of the blood vessel endothelium growth factor receptor 1 are arranged sequentially from an amino terminal to a carboxyl terminal. An experiment proves that the fusion protein vessel endothelium growth factor receptor (VEGFR)-1/Fc and a vessel endothelium growth factor (VEGF) have good affinity, the KD value reaches 265pm, the VEGFR-1/Fc can inhibit proliferation and migration of vessel endothelium cells and chick embryo chorioallantoic membranes and vessel growth of naked mouse. The fusion protein VEGFR-1/Fc has wide application in tumor therapy.

A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1⁺ bone marrow-derived cells to prior levels.